BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases
NEW YORK, July 12, 2023 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (N... Regenerative Medicine, Personnel BrainStorm Cell Therapeutics, NurOwn, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Media News - July 11, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Investor Update - July 11, 2023 Category: Pharmaceuticals Source Type: news
CAR T Cells Derived From Stem Cells Open Door To Universal Donor Cell Lines
Induced pluripotent stem cells (iPSC), a continuing muse in cell therapy research, could potentially be used to improve flaws associated with conventional CAR T therapy. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 10, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells
Engraftment of Vertex Pharmaceutical ' s VX-880 stem cell –derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 3, 2023 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news
Are human embryo models a cause for hope or alarm?
A recent breakthrough in the race to create ‘synthetic’ embryos has sparked criticism. But the findings could be valuable in understanding miscarriages and genetic disordersThe news on 14 June that scientists had made “synthetic human embryos” caused widespread surprise and alarm. Sounds scary, right? Perhaps even, as aneditorial in theGuardian suggested, like “playing God” and paving the way towards a dystopian “brave new world”.The reality is different. For one thing, calling these “synthetic embryos” is rather misleading, even prejudicial – most scientists prefer the term “embryo models”, and t...
Source: Guardian Unlimited Science - July 1, 2023 Category: Science Authors: Philip Ball Tags: Embryos Science Biology Ethics Stem cells Medical research Genetics Source Type: news
Cells from Cadaver Pancreas May Help Treat Type 1 Diabetes
One product, from cadaver donors, has just been approved by the FDA. The other, made from stem cells, is showing promise in a clinical trial. (Source: WebMD Health)
Source: WebMD Health - June 30, 2023 Category: Consumer Health News Source Type: news
Scientists Use Stem Cells to Replicate Early Human Embryo
FRIDAY, June 30, 2023 – Scientists hope to learn more about the earliest stages of human development using models of embryos created from stem cells.
The models, from University of Cambridge scientists, could ultimately shed light on why and how... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 30, 2023 Category: General Medicine Source Type: news
Beta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes? Beta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?
Anne L. Peters, MD, discusses clinical trial results of beta cells made from stem cells in patients with type 1 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 28, 2023 Category: Allergy & Immunology Tags: Diabetes & Endocrinology Commentary Source Type: news
Scientists use stem cells to create models of human embryos and study our earliest days
Scientists have created embryo models to help study the mysteries of early human development, the medical problems that happen before birth and why many pregnancies fail (Source: ABC News: Health)
Source: ABC News: Health - June 27, 2023 Category: Consumer Health News Tags: Health Source Type: news
FDA approves Roche ’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed period of time,Columvi provides patients with a treatment end date and potential time off treatmentColumvi is part of Roche ' s industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approvedLunsumioto treat follicular lymphomaBasel, 16 June 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Source: Roche Media News - June 27, 2023 Category: Pharmaceuticals Source Type: news
Two T1D Patients Achieve Insulin Independence After Stem Cell Transplants
(MedPage Today) -- SAN DIEGO -- Stem cell-derived islet cell therapy continued to show promise for the management of type 1 diabetes (T1D) with severe hypoglycemia, according to results from a small phase I/II clinical trial.
All six Part A... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 27, 2023 Category: Primary Care Source Type: news
At $20K, Stem Cell Eye Injections May Also Cost Patients Their Sight
(MedPage Today) -- George Gibson remembers turning to his wife after a 2015 procedure at a Florida clinic that he thought would help his failing eyesight.
At the hotel room where they were staying, he went to open his eyes, but he thought his... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 26, 2023 Category: American Health Source Type: news
Human Embryo Models Made in Lab
Four teams have coaxed human stem cells to organize themselves into embryo-like forms. The advance could shed light on fertility. (Source: NYT Health)
Source: NYT Health - June 24, 2023 Category: Consumer Health News Authors: Carl Zimmer Tags: your-feed-science Embryos (Human) Biology and Biochemistry Research Infertility Science and Technology Source Type: news
Experimental Prophylaxis Beneficial for Patients Undergoing HSCT
FRIDAY, June 23, 2023 -- For patients with hematologic cancer undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), graft-versus-host-disease (GVHD)-free, relapse-free survival is more common among those receiving... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2023 Category: Pharmaceuticals Source Type: news
